Lonza buys Shire’s U.S. clinical manufacturing site
Lonza buys U.S. clinical manufacturing site from Shire
ZURICH (Reuters) – Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.
The site in California has a successful regulatory track record and includes single-use bioreactors and associated downstream capabilities, Lonza said. The site employs more than 100 staff who will have the chance to keep working for Lonza, it added.
Reporting by Michael Shields